Market analysts predict the spine biologics market will top $2.6 billion by 2022, growing at a 4.4 percent compound annual growth rate, according to a Market Research Engine report.
Here are three observations:
1. Pushing the market forward are innovative technology advancements, demand for minimally invasive spine surgery and newly developed spine treatments.
2. The market will need to overcome unfavorable reimbursement policy, high costs and lack of professional expertise during the forecast period.
3. Top market players include DePuy Synthes, Precision Spine, Medtronic and Stryker.